Skip to main content
Clinical Trials/ACTRN12622001247763
ACTRN12622001247763
Completed
未知

Open label trial to assess safety and tolerability of ultrasound mediated mesalazine rectal suspension enema in healthy participants

Suono Bio0 sites10 target enrollmentSeptember 15, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Suono Bio
Enrollment
10
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 15, 2022
End Date
May 29, 2023
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Suono Bio

Eligibility Criteria

Inclusion Criteria

  • \* Undergoing routine colonoscopy procedure
  • \* Signed informed consent

Exclusion Criteria

  • \* Current known presentation of hemorrhoids or rectal bleeding
  • \* Pregnant or breast feeding
  • \* History of salicylate allergy
  • \* Previous bowel resection
  • \* Clinically significant hepatic or renal disease
  • \* Participating in a clinical trial within 1 month
  • \* History or signs of IBD (Crohn’s disease, UC) or cancer
  • \* Insufficient / no preparation for colonoscopy
  • \* Currently taking 5\-ASA based oral medication
  • \* Currently taking anti\-coagulants or anti\-platelet agents

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A study to look at the effect of the study drug on heart muscle thickness, the amount of drug that ends up in the blood, and the safety and tolerability of study drug in Noonan syndrome patients.oonan syndrome hypertrophic cardiomyopathyMedDRA version: 14.1Level: PTClassification code 10029748Term: Noonan syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 14.1Level: PTClassification code 10020871Term: Hypertrophic cardiomyopathySystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2011-003392-10-GBovartis Pharma Services AG22
Recruiting
Phase 1
Phase I study of a Latanoprost Ocular Implant for treatment of Open Angle Glaucoma or Ocular Hypertension.
ACTRN12621001718831PolyActiva Pty Ltd6
Active, not recruiting
Phase 1
Study to evaluate the safety, tolerability, and efficacy of LOmitapide for the treatment of patients with Familial CHylomicroNEmia SyndromeFamilial Chylomicronemia SyndromeMedDRA version: 20.0Level: PTClassification code 10058108Term: DyslipidaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2018-002911-80-ITPRM|2121820
Completed
Phase 3
An open-label study to assess the safety, tolerability and multiple-dose phamacokinetics of AA4500 0.58 mg in subjects with Dupuytren's contractures.
ACTRN12610001045000Auxilium Phamaceuticals, Inc.12
Active, not recruiting
Phase 1
The VIOLIN Study: to Evaluate etravirine Tolerability, Pharmacokinetics With Other Antiretrovirals In Treatment Experienced Patients
EUCTR2010-023532-16-ROJanssen R&D Ireland211